{"entity":{"id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","aka":[],"tldr":"A phase 2 trial of carboplatin, paclitaxel / nab-paclitaxel, pembrolizumab, doxorubicin and other drugs in triple-negative breast cancer, run by M.D. Anderson Cancer Center, now recruiting.","summary":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06318897 by M.D. Anderson Cancer Center, with a registry enrolment figure of 28 participants, started 2024-05-29 and due to reach its primary completion in 2027-09-30. Interventions recorded: Carboplatin; Paclitaxel; Pembrolizumab; Doxorubicin; Cyclophosphamide. Conditions listed: Stage 1 cT1b-T1cN0M0; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Participants must have histologically confirmed ER negative, PR negative and HER2-negative (TNBC) defined as ER\\<10%, PR\\<10%, and HER2 negative (per 2018 ASCO CAP guidelines)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06318897","url":"https://clinicaltrials.gov/study/NCT06318897"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","paclitaxel","pembrolizumab","doxorubicin","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06318897","phase":"2","setting":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer","sponsor":"M.D. Anderson Cancer Center","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06318897/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}